Screener
Amgen AMGN Change in Accrued Sales Incentives
Change in Accrued Sales Incentives at other companies
Other financials
Where this comes from
Reported directly by Amgen in its filing.
Tagged under the XBRL concept amgn:IncreaseDecreaseInSalesIncentivesAndAllowance.
The source filing: Amgen’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000318154-26-000126
| Line item | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Accrued income taxes, net | (60) | (2,313) |
| Long-term tax liabilities | 148 | 162 |
| Accrued liabilities | (58) | (50) |
| Accrued sales incentives and allowance | 278 | 1,113 |
| Other liabilities | (107) | (70) |
| Net cash provided by operating activities | 6,191 | 3,671 |
| Cash flows from investing activities: | ||
| Purchases of property, plant and equipment | (1,225) | (780) |
Item 1. FINANCIAL STATEMENTS
FAQ
- What is Amgen's change in accrued sales incentives?
- Amgen (AMGN) reported change in accrued sales incentives of $1.12B in Q2 2026.
- How has Amgen's change in accrued sales incentives changed year-over-year?
- Amgen's change in accrued sales incentives increased by 78.1% year-over-year, from $627M to $1.12B.
- What is the long-term trend for Amgen's change in accrued sales incentives?
- Over 3 years (2021 to 2024), Amgen's change in accrued sales incentives has grown at a 43.5% compound annual growth rate (CAGR), from $404M to $1.19B.
- What does change in accrued sales incentives mean?
- This metric tracks the change in liabilities related to rebates, discounts, and sales incentives offered to customers, such as wholesalers or pharmacy benefit managers. It is a critical indicator of the company's gross-to-net revenue adjustments and future cash outflows related to commercial contracts.
Ask your AI about Amgen's change in accrued sales incentives.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude